FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
Portfolio Pulse from Aaron Bry
The FDA has fully approved Biogen Inc.’s Alzheimer’s treatment, Leqembi, making it the first Alzheimer’s antibody treatment to reach full approval. Following this, Medicare announced it will cover the treatment under certain conditions. Other companies with Alzheimer’s treatments in the pipeline include Eli Lilly & Co, Cassava Sciences Inc, and Alzamend Neuro Inc.
July 07, 2023 | 4:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alzamend Neuro Inc is working on multiple Alzheimer’s treatments, including a cell-based vaccine. This could have a positive impact on the company's stock in the short term.
The development of multiple Alzheimer’s treatments by Alzamend Neuro, including a cell-based vaccine, could boost investor confidence in the company, potentially leading to an increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 70
POSITIVE IMPACT
Biogen's Alzheimer’s treatment, Leqembi, has been fully approved by the FDA. This is expected to have a positive impact on the company's stock in the short term.
The FDA approval of Biogen's Alzheimer’s treatment is a significant milestone for the company and is likely to boost investor confidence, leading to a potential increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Eli Lilly & Co’s Alzheimer’s treatment, Donanemab, has shown promising results in early trials. This could have a positive impact on the company's stock in the short term.
The promising results from early trials of Eli Lilly's Alzheimer’s treatment could boost investor confidence in the company, potentially leading to an increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 70
POSITIVE IMPACT
Cassava Sciences Inc's Alzheimer’s treatment, Simufilam, is advancing to a phase 3 trial. This could have a positive impact on the company's stock in the short term.
The advancement of Cassava Sciences' Alzheimer’s treatment to a phase 3 trial could boost investor confidence in the company, potentially leading to an increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 70